Aevi Genomic Medicine (Aevi Genomic Medicine) 5-Year RORE % : 0.00% (As of Sep. 2019)

Aevi Genomic Medicine 5-Year RORE % Chart

Aevi Genomic Medicine Annual Data
	Trend	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18
5-Year RORE %		Get a 7-Day Free Trial					-	-	-	-	-

Aevi Genomic Medicine Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
5-Year RORE %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aevi Genomic Medicine's 5-Year RORE %

For the Biotechnology subindustry, Aevi Genomic Medicine's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aevi Genomic Medicine's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aevi Genomic Medicine's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Aevi Genomic Medicine's 5-Year RORE % falls into.

Aevi Genomic Medicine 5-Year RORE % Calculation

Aevi Genomic Medicine's 5-Year RORE % for the quarter that ended in Sep. 2019 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2019 and 5-year before.

Aevi Genomic Medicine  (NAS:GNMX) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.

Aevi Genomic Medicine 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description